Moderna and IVI sign MOU for vaccine R&D partnership
The IVI - an international non-profit intergovernmental organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines – says the partnership will focus on accelerating vaccines for infectious diseases with high disease burden. Priority disease areas for the organization include chikungunya, shigella, salmonella, schistosomiasis, Group A Strep, Hepatitis E, HPV, and COVID-19 in addition to global health issues such as antimicrobial resistance.
“With IVI’s aim to drive innovative vaccine technology from need to global health impact, we look forward to working closely with a biotech company on the leading edge like Moderna,” said Dr. Jerome Kim, Director General of IVI.
In March, Moderna announced it would expand its global public health portfolio to 15 vaccine programs targeting priority pathogens that threaten global health, advancing vaccines into clinical studies by 2025. “Collaboration is a vital part in helping to achieve this vision,” said Dr. Paul Burton, Chief Medical Officer, Moderna.
Dr. Kim and Dr. Burton signed the MOU at IVI headquarters in Seoul, Republic of Korea yesterday.
